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ABSTRACT 
Metabolic syndrome (MetS) is by definition a multi system disorder, in which there is 
an accumulation of the different conditions that together increases the risk of Cardiovascular 
disease (CVD), Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD) and is 
related with a number of other disorders such as sleep apnea, polycystic ovarian disorder. 
Insulin resistance along with visceral adiposity, dyslipidemia and chronic subclinical 
proinflammatory state are the main characteristic features of the MetS. The main hypothesis 
of the study was to assess the prevalence of the MetS in patients with CVD and to estimate 
the age and gender wise distribution of the syndrome among the study population. The 
prevalence of the MetS was assessed in 180 patients who visited the Department of 
Cardiology using the definitions of IDF and revised NCEP ATP III. The prospective 
observational study revealed a prevalence of 41% (IDF) and 44% (revised NCEP ATP III) of 
the MetS among the study population. The prevalence of the MetS was found to be higher in 
women than men, based on the IDF definition: (female-51% and male-33%) and according to 
the revised NCEP ATP III criteria: (female-59% and male-33%). The MetS was found to be 
more prevalent in the study patients with the age >60years. The variables like Body Mass 
Index (BMI), Waist Circumference (WC), High Density Lipoprotein- cholesterol (HDL-c), 
Triglycerides (TG), Systolic and Diastolic Blood Pressure (BP) and Fasting Blood Glucose 
(FBS) were monitored. There was a significant association between the variables such as 
BMI, WC, BP and FBS (p<0.05) with the MetS. Amid the MetS driving the twin global 
pandemic of T2DM and CVD there is a devastating moral, medical and economic imperative 
to identify those individuals with the MetS early, so that lifestyle interventions and treatment 
may prevent the development of T2DM and CVD.   
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1. INTRODUCTION 
Cardiovascular disease (CVD) and Diabetes Mellitus (DM) collectively with cancer 
and chronic respiratory disease, are the world’s leading life-takers, causing an estimated 30 to 
40 million deaths each year, of which 70-80% are in low- and middle-income countries 
(WHO, 2008). In the midst of  the intensifying tide of DM around the world, the double 
jeopardy of CVD and DM is set to result in a flare-up of these and other cardiovascular 
complications if protective measure is not taken at the right time. Type II DM affects nearly 
200 million individuals’ world wide and its prevalence is rapidly increasing. CVD accounts 
for 50% of all the fatalities in people with DM. Subsequent to any cardiac event, people with 
DM have twofold times higher death rate than those without (Harris P et al., 2004). South 
Asia accounts for 30-40% of worldwide DM related Ischemic Heart Disease (IHD) deaths 
and 30% of stroke deaths (Colhoun HM et al., 2004). 
The Metabolic Syndrome (MetS) has been advocated as both a simple clinical tool for 
predicting DM and CVD, and the conceptual basis for understanding at least part of the 
pathophysiological link between metabolic risk, future DM and CVD. The clustering of 
metabolic risk factors with CVD and DM has been recognised for more than 80 years, but the 
modern concept of the MetS began when Gerald Reaven (American Endocrinologist, 
Stanford University School of Medicine, California, USA) proposed a conceptual framework 
which linked apparently distinct biological events into a single pathophysiological construct. 
This hypothesis argued that insulin resistance provided a common mechanism underlying the 
related abnormalities of blood pressure (BP), High Density Lipoprotein cholesterol (HDL-c), 
triglyceride (TG) and glucose tolerance. This pathophysiological concept was not proposed 
for clinical or epidemiological use. Later, a number of different definitions have been 
developed for this purpose by specialized organization like World Health Organization 
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(WHO), the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP 
III), the European Group for the Study of Insulin Resistance (EGIR) and most recently, the 
International Diabetes Federation (IDF).  
The history of MetS reflects the recognition of the concept of insulin resistance and its 
consequences as well as the recognition of adipose tissue as a physiologically active organ. 
Prof. Markolf Hanefield (Director of Centre for Clinical Studies Technical University, 
Dresden, Germany) and Dr. W Leonhardt was the first to say the term "Metabolic Syndrome” 
in 1981, they used the phrase to describe the combined prevalence of hyperlipoproteinemia, 
DM, hypertension, gout and obesity along with an increased prevalence of CVD, fatty liver 
and cholelithiasis. In 1985, Dr. Michaela Modan (Head, Biometry Unit, Department of 
Clinical Epidemiology, Chaim Sheba Medical Center, Israel) and his associates proposed a 
syndrome of insulin resistance or hyperinsulinemia as a common pathophysiological feature 
for obesity, hypertension and glucose intolerance, which could possibly explain their 
common association (Leslie B., 2005). 
Gerald Reaven in a 1988 lecture to the American Diabetes Association (ADA) 
proposed the name “Syndrome X”. According to GM Reaven, Syndrome X was a group of 
associated conditions that were important in the development of coronary artery disease and 
included hyperinsulinemia, glucose intolerance, hyperglycemia, elevated low density 
lipoprotein cholesterol and hypertension all resulting from resistance to insulin mediated 
glucose uptake. Syndrome X has also been called “Reaven's Syndrome”.  
The term "deadly quartet" was coined by Dr. Kaplan NM (Clinical Professor, 
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas) 
for the association of obesity, hypertension, hypertriglyceridemia and glucose intolerance in 
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which hyperinsulinemia played the key pathogenic role. Dr. Defronzo RA (School of 
Medicine University of Texas Health Science Center, San Antonio, USA) and Dr. Ferrannini 
E (Clinical Professor of Medicine, Diabetes Division, University of Texas Health Science 
Center. San Antonio, Texas, USA) developed the term "insulin resistance syndrome" to 
define a disease of Non-Insulin Dependant Diabetes Mellitus (NIDDM), arterial 
hypertension, dyslipidemia, atherosclerotic cardiovascular disease and obesity. Zimmet P 
(Director Emeritus and Foundation Head of WHO Collaborating Centre for the Epidemiology 
of Diabetes Mellitus) introduced the term "syndrome X plus" which included the elements of 
syndrome X as defined by Reaven GM, and also included upper body obesity, hyperuricemia, 
physical inactivity and aging. Finally, Hjerrman proposed renaming syndrome X as 
"metabolic cardiovascular syndrome" or "atherothrombogenic syndrome". In addition to the 
components of syndrome X, the presence of Low Density Lipoprotein cholesterol (LDL-c), 
HDL-c, Very Low Density Lipoprotein cholesterol (VLDL-c) and TG, even in the absence of 
hypercholesterolemia was also noticed by Hjerrman (Leslie B., 2005).  
MetS is a cluster of four main CVD risk factors such as obesity, insulin resistance 
(hyperglycemia), hypertension and dyslipidemia; among which obesity and insulin resistance 
are the indispensable components. The other important entities of MetS comprise of low-
grade inflammation, endothelial dysfunction, plasma hypercoagulability and atherosclerosis 
(Sidorenkov O et al., 2010). The prevalence of MetS is linked with standard of living, 
demographic, socio-economic, and genetic factors (Ferreira I et al., 2005). The various 
components such as age, BMI, postmenopausal status, diet rich in saturated fats, 
carbohydrates, and smoking have been positively related with MetS, while inverse links have 
been revealed for physical activity, education, income, and alcohol consumption (Park YW et 
al., 2003). MetS is a comprehensive disorder and an emerging clinical challenge. Clustering 
Introduction 
 
A Prospective Study on Metabolic Syndrome in Patients with Cardiovascular Disease 4 
 
together of hypertension, central obesity and dyslipidemia, with and without hyperglycemia 
is recognized for many decades and has been prospectively demonstrated in the Framingham 
study in the 1970s, and the Scandinavian studies in the 1980s (Bloomgarden ZT., 2002). 
The MetS consists of a group of heart disease hazard factors, including low HDL-c, 
elevated TG, impaired carbohydrate metabolism, central obesity, and high blood pressure 
(Reaven GM., 1988) (DeFronzo RA., 1991). People with MetS have twice the risk of 
cardiovascular disease and four times greater risk for developing diabetes (Grundy SM., 
2007). According to the IDF around 20-25 percent of the world’s population has the MetS 
when compared to the general population and they are twice as likely to die from and thrice 
as likely to have heart attack or stroke (Isomaa B et al., 2001). 
According to George Alberti (co-author of IDF consensus) “whichever definition is 
used and whatever variation in the numbers due to the different criteria, when looking at 
prevalence data for the MetS in different countries and across various ethnic groups, one fact 
is clear, universally, the MetS is a huge problem and is one that is growing at an alarming 
rate” (IDF consensus, 2006). Further the MetS is of special interest because it represents a 
composite disorder expressed by interconnected risk factors with unidentified genetic and not 
well known environmental influences (Kraja AT et al., 2005). A cardiovascular risk factor 
survey in France identified that elevated body weight, waist girth and low HDL-c were 
significantly larger contributors to the MetS in women than in men, whereas systolic and 
diastolic blood pressure contributed significantly less in women than in men (Dallongeville J 
et al., 2004). 
As central obesity is one of the factors included in the definition of the MetS, from the 
given Body Mass Index (BMI), central obesity is more common in men, is expected that 
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prevalence of the MetS would be higher in men than in women. Among non- diabetic 
European men and women from eight populations the prevalence of the MetS was generally 
higher in men than in women (Hu G et al., 2004). The effect of generalized obesity is also 
extremely important, in a population in which obesity is more common in women than in 
men. This pattern can be observed in Indian, Iranian and Turkish populations (Onat A et al., 
2002; Azizi F et al., 2003; Gupta A et al., 2003; Ramachandran A et al., 2003). 
The WHO defined MetS as insulin resistance and / or impaired glucose tolerance and 
two or more of the following:  
1) Waist-Hip ratio (WHR) >0.90 (men), >0.85 (women) or Body mass index (BMI) 
>30 kg/m
2
, 
2) TG >0.9 mmol/l (men), 1.7 mmol/l (women),  
3) BP >140/90 mmHg (or treated Hypertension)  
4) Microalbuminuria 
In 2001 the NCEP ATP III defined MetS, which was revised in 2005 by the American 
Heart Association/National Heart; Lung and Blood Institute. In the same year IDF proposed 
another definition. This definition laid prominence on abdominal obesity measured by the 
waist circumference. The other criteria include the elevated TG, decreased HDL-c, elevated 
BP and elevated fasting plasma glucose levels. 
The revised NCEP ATP III defined MetS as the occurrence of any three of the 
following five factors: 
i) Abdominal Obesity (Waist circumference): men > 90 cm; women > 80 cm (Asians) 
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ii) TG ≥ 150 mg/dl 
iii) HDL-c: men < 40 mg/dl; women < 50 m/dl 
iv) BP ≥ 130/ ≥ 85 mm Hg 
v) Fasting glucose ≥ 110 mg/dl 
The NCEP ATP III definition requires any three of the five criteria, whereas the IDF 
requires central obesity plus any of the other two abnormalities (Singh SM & Matoo SK., 
2008). A more recent definition by IDF stressed the importance of waist circumference 
strictly and regarding the ethnic/ race specific criteria (Marc DH et al., 2009). 
Amongst individuals with DM, hypertension or coronary heart disease (CHD) the 
prevalence of the MetS is considerably higher than the general population. For example, the 
prevalence of MetS using WHO criteria was between 76 and 92 per cent in various European 
populations of people with diabetes (Bruno G et al., 2004; Ilanne-Parikka P et al., 2004; 
Relimpio F et al., 2004). 
The MetS is a combination of a number of factors which may share a common 
etiology and each of which is a risk factor for CVD and or Type 2 DM. The clustering of 
CVD risk factors that depicts the MetS is now considered to be the driving force for a new 
CAD epidemic. It is expected that abdominal weight gain reduces the life expectancy by nine 
years due to obesity. Weight gain and obesity are associated with increased morbidity and 
mortality resulting in CHD, DM, Hypertension, cancer (in particularly of esophagus, colon, 
stomach, liver, gall bladder, pancreas, prostate in men & breast in women) and Gall bladder 
disease. In general the obese population was found to get three time increase in DM, insulin 
resistance and dyslipidemia (Nestel P et al., 2007). 
Introduction 
 
A Prospective Study on Metabolic Syndrome in Patients with Cardiovascular Disease 7 
 
CAD is the major cause of mortality and morbidity worldwide. A recent Finnish 
population based study suggested that Type 2 DM proven Myocardial Infarction (MI) have 
the same risk of MI as in non diabetics with proven MI (Qiao Q et al., 2009).  
In Asian Indians, there is an increasing pool of the MetS which is becoming a great 
concern, as much of it would convert to T2DM and CVD when effective interventions are not 
applied; thereby reversing the gains made through recent declining CVD mortality. Based on 
existing estimates, MetS affects almost 1/4th of the population in developed countries and the 
prevalence is still rising in developing countries, including India. 
A WHO expert consultation concluded that “the MetS may be useful as an 
educational concept but it lacks utility as diagnostic or management tool. The different 
definitions of the MetS hamper its epidemiological utility. It should not be applied as a 
clinical diagnosis. It is, however, good practice to control the other factors when one of the 
signs of the metabolic syndrome is seen” (Simmons RK et al., 2010). This statement 
dismisses the impression that identification of the MetS allows the identification of 
individuals with central obesity and cardiometabolic risk factors These individuals are at 
higher risk of clinical conditions such as T2DM, CVD, non-alcoholic fatty liver disease 
(NAFLD) and sleep apnea syndrome, but often the severity of the central fat accumulation, or 
other individual cardiometabolic risk factors is not alleged to demand pharmacological 
treatment because the individual factor(s) fall beneath thresholds for initiating drug treatment 
(Wild SH et al., 2011). 
“The FDA does not necessarily consider the MetS to represent a distinct disease 
entity” and according to the ADA and EASD (European Association for the Study of 
Diabetes) “the MetS requires much more study before its designation as a syndrome is truly 
warranted”. From a pragmatic perspective, providing a label to embrace possible components 
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of cardiovascular risk clusters acts as an aide memoire to prompt a search for, or monitoring 
of, other risk factor variables, with appropriate treatment of each emergent factor. As 
Shakespeare’s Juliet asked “What’s in a name?” MetS, or What you will, is a cardiovascular 
risk factor alert tag (Day C., 2007). 
While there have been several studies on the prevalence of CAD in DM particularly in 
South India and others, the exact prevalence of the MetS and the importance of the individual 
components in the development of CAD is not as much of investigated in India using the 
revised NCEP ATP III definition. A recent study on young north Indian patients with CAD 
confirmed the association with MetS, but the sample size was small and all the subjects were 
non diabetics with normal or impaired glucose tolerance (Achari V et al., 2006).  This study 
is an attempt to enhance the available knowledge in this field, as well as to compare its 
relative importance with known and established risk factors. Henceforth, research is needed 
to establish whether there is one single factor or several which interact to give the complete 
characteristic picture of the MetS in patients with CVD using both the definitions of IDF and 
revised NCEP ATP III. 
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2. REVIEW OF LITERATURE 
 A cross sectional study was carried out in 719 patients aged greater than 13years by 
Barbosa JB et al., (2010) in the outpatient department of cardiology clinic in Brazil, to 
assess the prevalence of Metabolic Syndrome (MetS) and the related components along with 
the relationship between the two diagnostic criteria. They concluded that the prevalence of 
MetS was higher in both genders when using International Diabetes Federation (IDF) 
definition (62.3% in men and 64.6% in women) than when using the National Cholesterol 
Education Program Adult Treatment Plan III (NCEP ATP III) (48.9% in men and 59% in 
women) and hypertension was the most prevalent factor. 
Wilson PWF et al., (2010) investigated whether MetS was a precursor of 
cardiovascular disease (CVD) and Type 2 Diabetes Mellitus (T2DM). A cohort study was 
conducted in 3323 middle-aged adults over an 8-year period to study the development of 
CVD and T2DM. During baseline in people without CVD or T2DM, the prevalence of the 
MetS was found to be 26.8% in men and 16.6% in women. The study concluded that MetS is 
commonly associated with an increased risk for CVD and T2DM in both genders. 
In 2009 Misra R et al., studied the prevalence of diabetes, MetS and cardiovascular 
risk factors among 1038 randomly selected Indian immigrants in the United States, aged from 
18 years. The prevalence rate of Diabetes Mellitus (DM) was found to be 17.4%, and pre-
diabetes was found in 33% of the subjects. Cardiovascular risk factors, mainly higher levels 
of Triglyceride (TG), Total Cholesterol (TC), Low Density Lipoprotein cholesterol (LDL-c), 
homocysteine, and C-reactive protein, and lower levels of High Density Lipoprotein 
cholesterol (HDL-c), were observed. The age-adjusted incidence of MetS was established to 
be 26.9% by using the original NCEP ATP III criteria, 32.7% by the revised NCEP ATP III 
criteria, and 38.2% by the IDF criteria.  
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A survey was conducted in United States by Ford ES et al., (2004), amongst 6,436 
men and women aged from 20 years with the National Health and Nutrition Examination 
Survey (NHANES) III (1988–1994) and about 1,677 participants from NHANES 1999–2000, 
using the NCEP ATP III definition. The study concluded that the unadjusted prevalence of 
the MetS was 23.1% in NHANES III and 26.7% in NHANES 1999–2000, and the age-
adjusted prevalence were 24.1% in NHANES III and 27.0% in NHANES 1999–2000. The 
age-adjusted prevalence increased by 23.5% in women and 2.2% in men. 
Sawant A et al., (2011) conducted a population-based survey in the metropolitan city 
of Mumbai. About 548 subjects, who attended the evaluation camp, were included in the 
study. The revised NCEP ATPIII was used to define MetS, and found that almost 95% of the 
participants had at least one abnormal factor. The prevalence of MetS was about 19.5%. The 
prevalence of MetS in males was nearly twice than females. The overall prevalence of Body 
Mass Index (BMI) (>23 kg/m
2
) was about 79.01%.  Hypertriglyceridemia and decreased 
levels of HDL-c were found to be more in males. 
A study was undertaken by Afsana F et al., (2010) in Dhaka Bangladesh to identify 
the parameters of MetS to predict CVD and Peripheral Vascular Disease (PVD). A total of 
360 subjects were selected; among them 260 subjects  were categorized in group 1 , who 
reported for Coronary Angiogram (CAG) and 100 subjects (group 2) were selected from 
outpatient department, coming for follow up with no past history of Coronary Artery Disease 
(CAD). Among the subjects 64.6% of group 1 and 66% of group 2 subjects had MetS. 
Among the CAG positive subjects 38.83% had single, 30.09% had double and 31.08% had 
triple vessel disease, 62.1% had increased waist circumference (WC), 90% had dyslipidemia 
and dysglycemia. This study reveals that hypertriglyceridemia, WC and hypertension are 
highly significantly while PVD is not higher in CAG positive subjects and there is no 
evidence of the relationship between MetS and PVD. 
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In this study, Hwang IC et al., (2011) investigated whether and to what extent MetS 
and its individual components are related to the risk of CVD in Korean population. Data from 
the 2005 Korea National Health and Nutrition Examination Survey were used for the study. 
The study sample consisted of 1,406 Korean adults (587 men, 819 women) who were 
diagnosed with MetS based on the revised NCEP ATP III criteria. The CVD prevalence 
among the subjects was 6.8% for men and 8.6% for women. Fasting glucose level was the 
highest predicting factor for CVD in Korean patients with MetS based on the revised NCEP 
ATP III definition. 
Yang T et al., (2012) explored the association between MetS related indicators and 
the ten-year risk for CVD in the middle-aged and elderly population. Data were collected 
from residents in Southern Taiwan through a health screening program, carried out from 
March 2007 to May 2008. Subjects with abdominal obesity and hypertension had 
significantly higher risk for CVD than those who had normal WC and blood pressure (BP). 
Subjects with hypertriglyceridemia were 1.86 times more at risk for developing medium risk 
of CVD than those who had normal triglyceride levels. Moreover, individuals with decreased 
HDL-c had significantly higher risk for CVD than those who had normal HDL-c. It was 
revealed that WC, BP, TG and HDL-c might be the positive indicators for predicting the risk 
of CVD for middle-aged and elderly populations. 
In Canadian adults Brenner DR et al., (2011) explored the changes in the profile of a 
number of metabolic and inflammatory markers associated with cardiometabolic disease at 
various stages of MetS. Serum levels of apolipoprotein A1 and B (Apo- A1 and B), HDL-c, 
fibrinogen, glycosylated haemoglobin (HbA1C) and homocysteine were determined in 1,818 
non-diabetic adults (16-79 years of age) from the Canadian Health Measures Survey. The 
prevalence of the MetS was 8.9%, with 31.8% having atleast one component in common. 
Metabolic markers such as HDL-c, Apo-B and HbA1C were increased significantly whereas 
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Apo-A was decreased. A significant association was observed between the MetS components 
and C-reactive protein and fibrinogen, but not homocysteine.  
The association of BMI and MetS along with the risk of CVD in middle-aged men of 
Sweden was investigated by Arnlov J et al., (2010). About 1758 participants without 
diabetes of 50 years age were assessed for cardiovascular risk factors. During follow-up 
(median 30 years), 681 developed CVD. Middle-aged men with MetS had greater risk for 
coronary events. In contrast to earlier reports, overweight and obese persons without MetS 
also had an increased risk of CVD. 
A population based, prospective cohort study was conducted by Lakka HM et al., 
(2002) to assess the association of MetS with cardiovascular and overall mortality in about 
1209 Finnish middle aged men without CVD, cancer or DM, aged 42-60 years at baseline. 
CVD and all-cause mortality are higher in men with MetS, even in the absence of baseline 
CVD and DM. The prevalence of MetS ranged from 8.8% to 14.3% depending on World 
Health Organization (WHO) and NCEP ATP III definition. 
A systemic review and meta analysis conducted by Mottillo S et al., (2010) identified 
87 studies which included 9,51,083 patients (NCEP ATP III: 63 studies, 4,97,651 patients; 
revised NCEP ATP III: 33 studies, 4,53,432 patients).There was little difference between the 
cardiovascular risk related with NCEP ATP III and revised NCEP ATP III definitions. When 
both definitions were evaluated MetS was associated with an increased risk of CVD. Patients 
with MetS, but without DM, had a higher choice of cardiovascular risk. 
Sidorenkov O et al., (2010) did a cross sectional study on 3555 adults aged between   
18-90 years in Russia. MetS was defined using IDF and NCEP ATP III criteria. Factors such 
as BMI, age, serum Gamma-glutamyltransferase (GGT), C-reactive protein and Aspartate 
aminotransferase (AST) to Alanine-aminotransferase (ALT) ratio were correlated with MetS 
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in both genders.  MetS was associated with sedentary lifestyle and smoking in women and 
men respectively. In the same regression model drinking alcohol 2-4 times a month and 
consumption of five or more alcohol units at one occasion in men, and drinking alcohol 5 
times or more a month in women were inversely associated with MetS. After a 9-year follow-
up, MetS was associated with higher risk of death from stroke and from either stroke or 
myocardial infarction (MI) in men. A positive association between MetS and mortality were 
observed for deaths from stroke and or MI in men. 
Guzder RN et al., (2006) investigated the prognostic implication of MetS according 
to revised NCEP ATP III criteria and the implication of individual features of MetS on CVD 
and Coronary Heart Disease (CHD) in a 5-year community based study of people with newly 
diagnosed T2DM About 562 participants aged 30-74 were grouped into a cross sectional 
study and 428(without CVD) participants into a prospective analysis. MetS was 
independently associated with CVD and CHD on diagnosis of T2DM. Increased age, female 
gender, TC and lipid-lowering therapy were also independent predictors of the risk. MetS at 
baseline was associated with an increased risk of CVD in the 5 years following diagnosis of 
T2DM. With the increase in MetS features, there was a decline in the CVD-free survival 
rates.  
Chien KL et al., (2008) investigated the distribution, agreement and classification 
patterns of MetS among the ethnic Chinese population. A total of 6610 (women, 42.5%) 
adults (mean age, 52.3 years) were included in the study. The criteria of MetS was divided 
into two groups: those with a major component required (WHO, EGIR [European Group for 
the Study of Insulin Resistance], AACE [American Association of Clinical Endocrinologist], 
IDF) and those with equal component (ATP III, American Heart Association/National Heart, 
Lung and Brain Institute [AHA/NHLBI], with modifications). The highest standardized rates 
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were in Asian AHA criterion, up to 29.8% in men and 25.6% in women. The lowest rates 
were in WHO criterion, 8.8% in men and 8.0% in women. 
 Al-Shaiji et al., (2007) determined the prevalence of MetS and the main 
characteristics associated with it, of adults attending two obesity clinics in Kuwait. A cross 
sectional study using the data collected from 617 adults aged 15 years and over was selected. 
Most of the patients were found to be obese (74.2%); along with low HDL-c, 
hypertriglyceridemia, increased WC, and high BP. The prevalence of MetS using NCEP ATP 
III was 46.8%. 
A prospective study was conducted in the Northern region of Ghana by Titty FK 
(2010), to establish the relationship between glycemic control, dyslipidemia and MetS. The 
incidence of good glycemic control, poor glycemic control, dyslipidemia and MetS among 
the patients were 96 (40.0%), 144 (60.0%), 164 (68.3%) and 104 (43.3%) respectively. 
Dyslipidemia occurred in 56 (58.3%) of the patients with good glycemic control and 108 
(75.0%) of those with poor glycemic control. MetS was diagnosed according to               
NCEP ATP III criteria and occurred in 32 (33.3%) of the patients with good glycemic control 
and 72 (50.0%) of the patients with poor glycemic control. 
Jordan HT et al., (2012) studied the prevalence of and factors associated with MetS 
among adult New York City residents aged 20 years or older with the help of the 2004 New 
York City Health and Nutrition Examination Survey. The prevalence of MetS and its 
components was defined by the revised NCEP ATP III guidelines, among a probability 
sample of 1,263 participants. The age-adjusted prevalence of MetS was 26.7%. The incidence 
was highest among Hispanics (33.9%) and lowest among Whites (21.8%). The occurrence 
increased with age and BMI and was higher among women (30.1%) than men (22.9%). The 
most frequent combination of metabolic abnormalities was abdominal obesity, elevated 
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fasting blood glucose, and BP. After adjusting for other factors, higher BMI, Asian race, and 
current smoking were positively relatively with MetS; alcohol use was inversely associated 
with MetS among women but increased the likelihood of MetS among men. 
A cross-sectional survey on the MetS and associated risk factors was performed by 
Kaur P et al., (2010). The MetS was defined using IDF and using revised NCEP ATP III 
criteria. The analysis of the obtained data revealed the prevalence of the MetS as 41.3% and 
51.4% using IDF and AHA/NHLBI criteria respectively. The prevalence of MetS was very 
high in the industrial population of south India.  
A cross sectional study by Das M et al., (2010) was carried among 350 individuals 
aged 30 years and above, of which 184 and 166 were men and women respectively. The 
prevalence was significantly higher in females (48.2%) when compared to males (16.3%). It 
was observed that males without MetS had significantly higher WC, waist-hip ratio, TG, 
Very Low Density Lipoprotein cholesterol (VLDL-c) and fasting blood glucose as compared 
to females without MetS.  
The prevalence of DM and MetS in Slovakia was explored by Mokan M et al., 
(2008), among 1517 subjects. The prevalence of MetS according to NCEP ATP III criteria 
was found to be 20.1% i.e.(15.9% in males and 23.9% in females) and 38.1% according to 
IDF criteria (39.7% in males and 36.6% in females). The most widespread MetS component 
was lower levels of HDL-c among the subjects. 
Using the data from the National Health and Nutrition Survey 2006 Rojas R et al., 
(2010) examined the prevalence of Mets and its contributing risk factors in Mexican adults 
aged 20 years and older. In accordance with definitions by the NCEP ATP III, AHA/NHLBI, 
and IDF, the prevalence of MetS was 36.8, 41.6 and 49.8%, respectively. Women were more 
affected than men due to the higher prevalence of central obesity among females. Prevalence 
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of MetS increased with age and was higher among populations living in metropolitan areas, 
in the west-central region, and those with lower education. 
Luksiene DI et al., (2010) compared the prevalence of the MetS using three different 
definitions and evaluated its associations with Ischemic Heart Disease (IHD) in Kaunas adult 
population of Lithuania. A total of 1336 subjects aged 35–64 years (603 men and 733 
women) were included in the study. The MetS was defined by the WHO, NCEP ATP III, and 
IDF criteria. IHD was diagnosed based on if a documented history of myocardial infarction, 
angina pectoris, or ischemic changes on electrocardiogram were predominant. The MetS 
diagnosed using the WHO definition was not associated with a significant risk of IHD in men 
and women. When using the IDF criteria the prevalence of MetS was relatively higher in both 
genders.  
A study was conducted in a cardiac center in Patna, India by Achari  V et al., (2006) 
investigated the prevalence of MetS and its association with CAD in 928 (602 males, 326 
females) patients with T2DM using the criteria of Alberti and Zimmet. Of which 596 (64.2%) 
found to have MetS and 516 (55.6%) had chances for CAD. When the individual components 
of the MetS were tested for their relationship with CAD, it was found that obesity and 
microalbuminuria had the strongest association with the presence of IHD. Hypertension 
showed a weaker correlation while elevated TG levels showed no association. Smoking was 
strongly associated with the presence of CAD. The other factors associated with CAD were 
MetS, obesity, hypertension, nephropathy, age and smoking.  
A cross-sectional study was conducted in a primary care hospital by                  
Cortes-Diaz N et al., (2011). About 16,856 individuals (age 58.1 +/- 15.1 years) were 
included in the study. The prevalence of MS adjusted for gender, age and region size 
according to the 2001 and 2004 NCEP-ATP III, IDF and AHA/NHLBI definitions was 
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28.4%, 32.8%, 65.5% and 69.4%, respectively. Hypertension was the most prevalent risk 
factor associated with CAD and stroke. In accordance to the AHA/NHLBI criteria, MetS 
appears to be the best predictor of CAD and stroke in the Portuguese population. 
In 2007 Saberi HR et al., (2011) conducted a cross sectional study to determine the 
prevalence of MetS among bus and truck male drivers in Kashan a city in Iran. From among 
the 429 subjects prevalence of MetS was 35.9% using NCEP ATP III criteria. Hypertension 
and DM were seen in 42.9% and 7% of the drivers respectively. High TG (53.4%) and low 
HDL-c levels (48.7%) were more common than other components of MetS. A significant 
positive relationship was seen between BMI, DM, high BP and MetS; but there was no 
association between MetS and smoking. 
A retrospective study conducted in Romania by Leon MM et al., (2010) identified the 
correlation between MetS and CVD. About 1463 patients were included in the study of which 
734 patients met the diagnostic criteria of cardiometabolic syndrome. The incidence of 
cardiometabolic syndrome was highly predominant on the age group 40-59 years (61.66%). 
Increased hypertension was found in the patient age group 48-69 years (53.70%) and lowest 
in the patients group 25-38 years (11.35%). The study concluded that MetS was a predictor of 
the occurrence and development CVD. 
In a community based cross sectional study Mangat C et al., (2010) determined the 
prevalence and socio-demographic factors associated with MetS in a total of 605 subjects 
adults aged 18 years and above in Chandigarh, India using the IDF and NCEP ATP III 
criteria.  By using the IDF definition, MetS was found in 287 (47.4%) subjects and it was 
more prevalent among females 171 (59.6%) as compared to males 116 (40.4%). By applying 
NCEP ATP III overall prevalence was less i.e. 233 (38.5%) but again its prevalence was 
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more among females 141 (44.8%) than males 116 (39.5%). Higher socioeconomic status, 
sedentary occupation and high BMI were significantly associated with MetS. 
A population based study on a sample of 5632 individuals aged 65-84 years at 
baseline conducted by Maggi S et al., (2006) assessed the prevalence of MetS by diabetic 
status and gender in the participants in the Italian Longitudinal Study on Aging (ILSA). The 
association of MetS with stroke, CHD, and DM at baseline and with CVD mortality at 4-year 
follow-up was measured. The prevalence of MetS was 25.9% in non-diabetic men and 55.2% 
in non-diabetic women; in diabetic individuals it was 64.9% and 87.1% in men and women, 
respectively. At baseline, in both men and women there was a significant association with 
stroke and DM. A significant association with CHD was found in men only. During the 
approximately 4-year follow-up, non-diabetic men with MetS had a risk of CVD mortality 
12% higher compared to those without MetS, whereas no significant differences were found 
in women. 
In Kuala Lumpur population Moy FM et al., (2010) studied the incidence of MetS 
using the IDF and the revised NCEP ATP III definitions and also verified if all participants 
have the same cardiometabolic risks. MetS was diagnosed in 41.4% and 38.2% participants 
using the revised NCEP ATP III and IDF criteria respectively. Participants diagnosed by the 
revised NCEP ATP III criteria had lower BMI and WC but had increased cardiometabolic 
risks than those diagnosed with both criteria. Their BP, fasting blood glucose, TC and TG 
were more adverse than the IDF group. This demonstrated that central obesity may not be a 
prerequisite for the development of increased cardiometabolic risks within the Malay 
population. 
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3. METHODOLOGY 
OBJECTIVES:  
 The pattern of Metabolic Syndrome (MetS) in patients with cardiovascular 
disease (CVD) remains ambiguous. This study sought to establish the prevalence of 
the MetS and the factors associated with this syndrome. 
 The aim of the study was to assess the prevalence of the MetS among patients 
with CVD using the revised National Cholesterol Education Program Adult Treatment 
Plan III (rNCEP ATP III) and International Diabetes Federation (IDF) definitions. 
 To assess the age related prevalence of the MetS among men and women. 
 To account for prevalence of different components associated with the MetS 
in men and women. 
 To determine the socio-demographic factors associated with the MetS. 
 To categorize and compare the MetS according to the criteria of              
rNCEP ATP III and IDF guidelines.  
STUDY DESIGN: 
A prospective observational study was conducted in the outpatient Department of 
Cardiology, Kovai Medical Center and Hospital, a multispecialty hospital in Coimbatore. It 
was approved by the KMCH ethics committee for research at Kovai Medical Center and 
Hospital, Coimbatore on 22-10-2011. 
STUDY SITE: 
The study was conducted in the outpatient Department of Cardiology, Kovai Medical 
Center and Hospital, a multi-specialty hospital in Coimbatore. 
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STUDY PERIOD: 
The study was carried over a period from June 2011 to December 2011 in Kovai 
Medical Center and Hospital, Coimbatore.  
INCLUSION CRITERIA: 
Both male and female patients having CVD were included in the study. 
EXCLUSION CRITERIA: 
Pregnant women and patients with abdominal ascites were excluded from the study. 
SOURCES OF DATA: 
The data was collected from various sources such as patient’s case report, treatment 
chart and laboratory reports. 
STUDY DESIGN PROTOCOL: 
Patients information such as demographics, socio-economic status, physical 
manifestation and also clinical manifestations like fasting blood glucose value, High Density 
Lipoprotein cholesterol (HDL-c), Triglycerides (TG), Total Cholesterol (TC) and Low 
Density Lipoprotein-cholesterol (LDL-c) during baseline and review were collected.  
The concept of MetS was defined according to the IDF guidelines and the diagnosis is 
made when increased waist circumference is present plus atleast two other risk factors. 
1. Central obesity: waist circumference(WC) ≥ 90 cm (male),  ≥ 80 cm (female)  
2. Dyslipidemia: TG ≥ (150 mg/dl)  
3. Dyslipidemia: HDL-c < 40 mg/dl (male), < 50 mg/dl (female)  
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4. Blood pressure (BP) ≥ 130/85 mmHg  
5. Fasting plasma glucose ≥ (110 mg/dl)  
The rNCEP ATP III (Asians) requires at least three of the following:  
1. Central obesity: WC ≥ 90 cm (male),  ≥ 80 cm (female)  
2. Dyslipidemia: TG ≥ (150 mg/dl)  
3. Dyslipidemia: HDL-c < 40 mg/dl (male), < 50 mg/dl (female)  
4. Blood pressure ≥ 130/85 mmHg  
5. Fasting plasma glucose ≥ (110 mg/dl) 
The rNCEP ATP III criteria suggested the cut-off values of WC should be ethnic 
specific, individuals of Asian origin should use the cut-off of 90 cm in men and 80 cm in 
women. In the case of rNCEP ATP III definition, abdominal obesity is a part of the syndrome 
but not a prerequisite for its diagnosis. The IDF’s diagnosis of MetS gives prominence on 
abdominal obesity as a mandatory factor plus any two of the other four criteria which are 
basically the same to those provided by rNCEP ATP III. The IDF definition uses ethnic-
specific waist circumference cut-off points as a prerequisite for diagnosis. Similar to the 
rNCEP ATP III criteria, IDF recommends cut-off levels of 90 cm in men and 80 cm in 
women for central obesity among Asians. For both criteria, we used the recommended cutoff 
for Asians (90 cm in men and 80 cm in women) as there are no nationalized cut-off values 
particularly for Indians. 
 Statistical Analysis 
The statistical package Graph Pad Prism (version 5.0) was used for statistical analysis. 
Differences of the mean values of baseline and review characteristics and prevalence of 
metabolic syndrome and its individual components of the MetS between the two study time 
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points were tested by χ2 test for categorical variables and odds ratio and relative risk was also 
calculated. Based on the definitions of IDF and rNCEP ATP III, patients were categorized 
and analyzed for clinical significance (p < 0.05) among study population. 
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4. TABLES AND GRAPHS 
 
Table 1: GENERAL CHARACTERISTICS OF THE STUDY SUBJECTS 
 
S. No. General Characteristics 
Male 
(Mean±S.E) 
Female 
(Mean±S.E) 
1 Number of Patients (%) 98(54%) 82(46%) 
2 Age in years 54±1.25 55.52±1.38 
3 BMI in kg/m² 27.27±0.38 28.20±0.34 
4 Waist Circumference in cm 87.97±0.92 84.26±0.82 
5 Systolic BP in mmHg 128.57±1.70 130.97±1.77 
6 Diastolic BP in mmHg 81.12±1.05 83.17±1.06 
7 FBS  in mg/100ml 132.61±6.09 156.02±8.33 
8 HDL-c in mg/100ml 47.84±0.98 40.24±1.02 
9 Triglycerides in mg/100ml 130.51±5.99 110.04±3.96 
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Figure 1: MEAN PHYSICAL VARIABLES OF THE STUDY POPULATION  
 
Figure 2: MEAN LABORATORY AND HEMODYNAMIC VARIABLES OF THE 
STUDY POPULATION  
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Table 2:  GENDER WISE DISTRIBUTION OF THE STUDY SUBJECTS  
 
S. No. Gender Total (n=180) Percentage 
1 Male 98 54% 
2 Female 82 46% 
 
 
 
Figure 3:  GENDER WISE DISTRIBUTION OF THE STUDY SUBJECTS 
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Table 3:  AGE WISE DISTRIBUTION OF THE STUDY POPULATION 
S. No. Age (Years) Total (n=180) Percentage (%) 
1 20-39 22 12.22 
2 40-59 100 55.56 
3 60-79 58 32.22 
 
 
 
 
Figure 4:  AGE WISE DISTRIBUTION OF THE STUDY POPULATION 
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Table 4: DISTRIBUTION OF THE SUBJECTS ACCORDING TO THE MARITAL 
STATUS 
 
S. No. Marital Status N=180 Percentage (%) 
1 Single 6 3.33 
2 Married 174 96.67 
 
 
 
 
 
 
Table 5: DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO THEIR 
SOCIAL HABITS 
 
S. No. Lifestyle Variables N=180 Percentage (%) 
1 Smoking 20 11.11 
2 Alcoholic 10 5.55 
3 Both Smoking & Alcoholic 40 22.22 
4 None 110 61.11 
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Table 6: DISTRIBUTION OF THE SUBJECTS ACCORDING TO THE 
EDUCATIONAL STATUS 
 
 
S. No. 
 
 
Educational Status 
 
N=180 Percentage (%) 
1 ≤ 8 78 43.33 
2 9 to 11 57 31.67 
3 ≥ 12 45 25.00 
 
 
 
Figure 5: DISTRIBUTION OF THE SUBJECTS ACCORDING TO THE 
EDUCATIONAL STATUS 
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Table 7: PREVALENCE OF MetS AMONG THE STUDY POPULATION BASED ON 
IDF CRITERIA 
 
S. No. Variables N=180 
Subject with MetS 
(N=74) 
Percentage 
(%) 
1 Age( in years) 
a. 20-39 
b. 40-59 
c. 60-79 
 
22 
100 
58 
 
6 
36 
32 
 
27.27 
36.00 
55.17 
2. Sex 
a.  Male 
b.  Female 
 
98 
82 
 
32 
42 
 
32.65 
51.22 
3. Marital status 
a. Single 
b. Married 
 
4 
176 
 
1 
73 
 
25.00 
41.47 
4. Educational status 
a.  ≤ 8 
b.  9-11 
c.  ≥ 12 
 
78 
57 
45 
 
42 
20 
12 
 
53.84 
35.08 
26.67 
5. Lifestyle Variables 
a. Smoking 
b. Alcoholic 
c. Both 
d. None 
 
20 
10 
40 
110 
 
6 
1 
27 
40 
 
30.00 
10.00 
67.50 
36.36 
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Table 8: PREVALENCE OF MetS AMONG DIFFERENT AGE GROUPS BASED ON 
IDF CRITERIA 
 
 
S. No. Age Group With MetS 
Without  
MetS 
P value 
1 20-39 6 16 
0.023* 2 40-59 36 64 
3 60-79 32 26 
       *p<0.05 
 
 
Figure 6: PREVALENCE OF METS AMONG DIFFERENT AGE GROUPS BASED 
ON IDF CRITERIA 
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Figure 7: GENDER WISE PREVALENCE OF METS ACCORDING TO IDF 
CRITERIA 
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Table 9: PREVALENCE OF METS WITH RESPECT TO EDUCATIONAL STATUS 
BASED ON IDF CRITERIA 
 
S. No. Educational status With MetS 
Without  
MetS 
P value 
1 ≤ 8 42 36  
0.007 2 9 – 11 20 37 
3 ≥ 12 12 33 
 
 
 
Figure 8: PREVALENCE OF METS WITH RESPECT TO EDUCATIONAL STATUS 
ACCORDING TO IDF CRITERIA 
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Table 10: IDF BASED DESCRIPTION OF METS ACCORDING TO BMI OF THE 
SUBJECTS 
 
S.No. BMI 
With MetS 
N=74 
Without 
MetS 
N=106 
Total 
N=180 
Percentage 
IDF 
 
P value 
1 18.5-24.9 9 44 53 16.98 
0.000* 2 25-29.9 29 19 48 60.42 
3 ≥30 36 43 79 45.57 
   *p<0.05 
 
 
Figure 9: IDF BASED DESCRIPTION OF METS ACCORDING TO BMI OF THE 
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ATP III DEFINITION 
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Table 11: PREVALENCE OF METS AMONG THE STUDY POPULATION BASED 
ON rNCEP ATP III 
S. No. Variables N=180 
Subject with 
MetS 
Percentage of 
rNCEP 
1 Age in years 
a. 20-39 
b. 40-59 
c.  60-79 
 
22 
100 
58 
 
06 
32 
42 
 
27.27 
32.00 
72.41 
2 Sex 
a. Male 
b. Female 
 
98 
82 
 
32 
48 
 
32.65 
58.54 
3 Marital status 
a. Single 
b. Married 
 
4 
176 
 
2 
78 
 
50.00 
44.32 
4 Educational status 
a. ≤ 8 
b.  9-11 
c. ≥ 12 
 
78 
57 
45 
 
44 
23 
13 
 
56.41 
40.35 
28.89 
5 Lifestyle Variables 
a. Smoking 
b. Alcoholic 
c. Both 
d. None 
 
20 
10 
40 
110 
 
5 
2 
26 
47 
 
25.00 
20.00 
65.00 
42.72 
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Table 12: PREVALENCE OF METS AMONG DIFFERENT AGE GROUPS BASED 
ON rNCEP ATP III DEFINITION 
 
 
S. No. 
 
Age Group With MetS Without MetS P value 
1 20-39 6 16 
0.001* 2 40-59 32 68 
3 60-79 42 16 
    *p<0.05 
 
 
Figure 11: PREVALENCE OF METS AMONG DIFFERENT AGE GROUPS BASED 
ON rNCEP ATP III DEFINITION 
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Table 13: PREVALENCE OF METS IN REGARD TO EDUCATIONAL STATUS 
BASED ON rNCEP ATP III DEFINITION 
 
 
S. No. Educational 
status 
With MetS 
 
Without  MetS P value 
1 ≤ 8 44 34 
0.009 
2 9 – 11 23 34 
3 ≥ 12 13 32 
            
 
Figure 12: PREVALENCE OF METS IN REGARD TO EDUCATIONAL STATUS 
BASED ON rNCEP ATP III DEFINITION 
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Table 14: CATEGORIZATION OF THE SUBJECTS WITH RESPECT TO BMI 
BASED ON rNCEP ATP III DEFINTION 
 
S.No. BMI 
With 
MetS 
N=80 
Without 
MetS 
N=100 
Total 
N=180 
Percentage 
of rNCEP 
P value 
1 18.5 – 24.9 11 42 53 20.75 
0.000* 2 25 – 29.9 30 18 48 62.50 
3 ≥ 30 39 40 79 49.36 
    *p<0.05 
 
Figure 13: CATEGORIZATION OF THE SUBJECTS WITH RESPECT TO BMI 
BASED ON rNCEP ATP III DEFINTION 
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Table 15: COMPARING THE PREVALENCE OF METS BY USING IDF AND rNCEP 
ATP III DEFINITIONS 
 
 
Gender N=180 MetS by IDF 
Percentage 
IDF 
MetS by 
rNCEP 
Percentage 
rNCEP 
Male 98 32 32.65 32 32.65 
Female 82 42 51.22 48 58.53 
Total 180 74 41.11 80 44.44 
 
 
 
Figure 14: COMPARING THE PREVALENCE OF METS BY USING IDF AND 
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Table 16: COMPARISON OF THE STUDY POPULATION ON BASELINE AND REVIEW   
 
S. No. General Characteristics 
BASELINE (N=180) REVIEW (N= 104) 
MALE 
(MEAN±S.E) 
FEMALE 
(MEAN±S.E) 
MALE 
(MEAN±S.E) 
FEMALE 
(MEAN±S.E) 
1 Age in years 54±1.25 55.52±1.38 51.65±1.23 50.54±1.19 
2 BMI in kg/m
2
 27.27±0.38 28.20±0.34 27.75±0.49 28.72±0.45 
3 Waist Circumference in cm 87.97±0.92 84.26±0.82 87.88±1.15 86.40±0.94 
4 FBS in mg/100ml 132.61±6.09 156.02±8.33 124.15±7.01 110.63±5.90 
5 HDL-c in mg/100ml 47.84±0.98 40.24±1.02 48.53±1.07 39.75±1.58 
6 Triglycerides in mg/100ml 130.51±5.99 110.04±3.96 132.1±8.20 120.75±6.36 
7 Systolic BP in mmHg 128.57±1.70 130.97±1.77 131.83±2.02 129.77±2.61 
8 Diastolic BP in mmHg 81.12±1.05 83.17±1.06 83.33±1.29 83.40±1.45 
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Table 17: CHARACTERISTICS OF SUBJECTS ACCORDING TO IDF CRITERIA 
VARIABLES 
 
WITH 
METS 
 
WITHOUT  
METS 
OR 95%CI RR 95%CI P value 
W.C        
Abnormal 
Normal 
74 
0 
32 
74 
341.55 
20.53 to 
5681.69 
  0.0001* 
Laboratory Variables        
 TG        
Abnormal 
Normal 
20 
54 
18 
88 
1.81 0.88 to 3.72 1.59 0.91 to 2.79 0.1059 
HDL-c        
Abnormal 
Normal 
42 
32 
58 
48 
1.08 0.59 to 1.97 1.03 0.79 to 1.35 0.7856 
FBS        
Abnormal 
Normal 
45 
29 
36 
70 
3.02 1.63 to 5.59 1.79 1.29 to 2.47 0.0004* 
Hemodynamic Variables        
Systolic BP        
Abnormal 
Normal 
60 
14 
38 
68 
7.67 3.79 to 15.51 2.26 1.71 to 2.98 0.0001* 
Diastolic BP        
Abnormal 
Normal 
57 
17 
39 
67 
5.76 2.95 to 11.26 2.09 1.58 to 2.76 0.0001* 
*p<0.05 
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Table 18: CHARACTERISTICS OF SUBJECTS ACCORDING TO rNCEP ATP III DEFINITION  
VARIABLES 
 
WITH 
METS 
 
WITHOUT  
METS 
OR 95%CI RR 95%CI P value 
W.C        
Abnormal 
Normal 
74 
6 
32 
68 
26.21 10.31 to 66.56 2.89 2.16 to 3.87 0.0001* 
Laboratory Variables        
TG        
Abnormal 
Normal 
21 
59 
17 
83 
1.74 0.84 to 3.57 1.54 0.87 to 2.72 0.1337 
HDL-c        
Abnormal 
Normal 
48 
32 
52 
48 
1.39 0.76 to 2.51 1.15 0.89 to 1.49 0.2802 
FBS        
Abnormal 
Normal 
51 
29 
30 
70 
4.10 2.19 to 7.67 2.12 1.50 to 2.99 0.0001* 
Hemodynamic Variables        
Systolic BP        
Abnormal 
Normal 
67 
13 
31 
69 
11.47 5.53 to 23.79 2.71 1.99 to 3.68 0.0001* 
Diastolic BP        
Abnormal 
Normal 
63 
17 
33 
67 
7.52 3.82 to 14.83 2.39 1.76 to 3.23 0.0001* 
*p<0.05 
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5. RESULTS AND DISCUSSION 
Metabolic syndrome (MetS) is an accumulation of the different conditions that together 
increases the risk of Cardiovascular Disease (CVD), Diabetes Mellitus (DM), Chronic Kidney 
Disease (CKD) and is related with a number of other disorders such as sleep apnea, polycystic 
ovarian disorder (Peters C., 2007). MetS has been shown to increase the risk of CVD morbidity 
and all-cause mortality. The prevention and reduction of the MetS is essential to reduce CVD 
and to extend the life of adult population (Mottillo S et al., 2010). The pathogenesis of the 
syndrome is multifaceted and so far the comprehensive mechanism of causation or its 
pathophysiology is not completely recognized, however obesity, sedentary lifestyle, dietary 
factors, and genetic factors are known to interrelate in the development of the syndrome 
(Cornier et al., 2008). World Health Organization (WHO) [WHO 1999] was the first to propose 
the criteria for diagnosis of MetS, followed by European Group for the Study of Insulin 
Resistance (EGIR) [Balkau B et al., 1999]. In WHO and EGIR definitions, the presence of 
insulin resistance was a prerequisite. The National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III (ATP-III) assigned MetS as a secondary target for intervention 
(Adult Treatment Panel 2001). In 2005, the International Diabetes Federation (IDF) presented a 
MetS definition (Alberti KG et al., 2005), in which central obesity was the prerequisite and 
different cut-off values for Waist Circumference (WC) were introduced for different ethnic 
groups. The American Heart Association and the National Heart, Lung and Blood Institute 
(AHA/NHLBI) revised the NCEP criteria by decreasing the glucose cutoff from 110 to 100 
mg/dl [Grundy SM et al., 2005]. And recently in the revised NCEP ATP III definition a new 
cut off value for the WC has been introduced for the South Asian population (≥ 90 cm [male],   
≥ 80 cm [female]).  
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A prospective observational study was performed to find out the prevalence of MetS 
using the definitions of revised NCEP ATP III and IDF and to study the impact of different 
variables such as age, gender, Body Mass Index (BMI), WC, Fasting Blood Sugar (FBS), High 
Density Lipoprotein cholesterol (HDL-c), Triglycerides (TG) and Blood Pressure (BP) on the 
study patients based on revised NCEP ATP III and IDF guidelines. A total of 180 patients who 
visited the Department of Cardiology at Kovai Medical Center and Hospital, Coimbatore from 
June 2011 to December 2011 were included in our study.  
The baseline characteristics of the study subjects were summarized in Table: 1. In the 
patients who visited the cardiology clinic, 54% (n=98) were males and 46% (n=82) were females 
within the age group of 20 to 80 years (Table: 2, Figure: 3). The age wise classification of the 
study patients revealed that 12.22% (n=22), 55.6% (n=100) and 32.22 % (n=58) were in the age 
group of 20-39 years, 40-59 years and 60-79 years respectively (Table: 3, Figure: 4). The mean 
age of the men and women patients in the study were 54±1.25 and 55.52±1.38 correspondingly 
(Table: 1). The average age of the study population was found to be 54.69±0.93 (Table: 16). 
Based on lifestyle our study subjects were categorized into smokers, alcoholics, both 
smokers and alcoholics and abstainers. It was found out that 22.22% were both smokers and 
alcoholic, whereas 11.11% were smokers and 5.55% were alcoholics alone (Table: 5). A higher 
number of the study population were found to be both smokers and alcoholics. All the earlier 
studies depict that smoking and alcohol consumption is a triggering factor for various health 
hazards in particularly cardiovascular and metabolic complications and so it can be established 
that these lifestyle variables can be a prompting factor leading to the MetS and in turn leading to 
cardiovascular complications (Jordan HT et al., 2012). 
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The study population was categorized based on the level of educational attainment as ≤ 8, 
9-11 and ≥ 12 standards. There was about 43% (n=78), 32% (n=57) and 25% (n=45) in ≤ 8, 9-11 
and ≥ 12 standards respectively. Majority of the study population who visited the cardiology 
clinic were having educational qualification ≤ 8 standard.  
The factors such as BMI, WC, BP, FBS, HDL-c and TG were measured and documented 
during the baseline to assess the possibility of the MetS. It was found that during baseline the 
mean BMI of men was found to be 27.27±0.38 kg/m
2
 and that of women was 28.20±0.34 kg/m
2
. 
The average BMI of the study patients was found to be 27.7±0.26 kg/m
2
. The mean WC of the 
male patients was illustrated to be 87.97±0.92 cm and that of females was 84.26 ± 0.82 cm. The 
average WC of our subjects was 86.29±0.64 cm. The means of the systolic and diastolic BP of 
men were found to be 128.5±1.70 mmHg & 81.12 ±1.05 mmHg and that of women were 
130.97±1.77 mmHg & 83.17±1.06 mmHg correspondingly. The mean systolic and diastolic BP 
of our study population was found to be 129.66±1.23 mmHg and 82.05±0.75 mmHg 
respectively. The other clinical parameters such as FBS, HDL-c, and TG of men were found to 
be 132.61±6.09 mg/100ml, 47.83±0.98 mg/100ml and 130.51±5.96 mg/100ml respectively and 
for women were 156.02±8.33 mg/100ml, 40.24±1.02 mg/100ml and 110.03±3.96 mg/100ml 
correspondingly (Table: 1 and Figures: 1 & 2). The average of FBS, HDL-c, and TG of the study 
patients were found to be 143.27±5.10 mg/100ml, 44.7±0.80 mg/100ml and 121.34±3.78 
mg/100ml respectively (Table: 16). 
The study patients were categorized based on the IDF and revised NCEP ATP III 
definitions (Tables: 7 and 11 respectively).  
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The prevalence of MetS in the study population using the IDF definition was illustrated 
to be 41%. Similarly to our result, when the IDF criteria was used in another study conducted in 
Arab population by Harzallah F et al., (2006) a prevalence of 45.5% was observed. Furthermore 
in another prospective cross sectional study conducted in Mangalore by Pemminatti S et 
al.,(2009) using the IDF criteria, a higher prevalence of the MetS was observed 57% (63.6% in 
women and 48.8% in men). All these prevalence of the MetS can be associated with our study. 
Among the 98 male and 82 female subjects, nearly 32 and 42 male and female patients 
respectively were observed to have the MetS according to the IDF definition. The gender wise 
prevalence of the syndrome in the study population was found to be 33% (n=32) for males and 
51% (n=42) females (Table: 7 and Figure: 7) when using the IDF criteria. It was observed from 
our study that a higher prevalence of the syndrome was revealed among the female study patients 
when using the IDF criteria. This gender wise prevalence is in accordance with a study 
conducted by Mangat C et al., (2010) in the highly urbanized Union Territory of North India, 
where the prevalence of the MetS was found in 287 (47.4%) subjects and it was more prevalent 
among females i.e. 171 (59.6%) as compared to males i.e. 116 (40.4%) when using the IDF 
definition. Similarly Rojas R et al., (2010) conducted a study in Mexico which also revealed a 
higher prevalence of the MetS in women (52.7%) than men (46.4%) when using the IDF 
definition. Numerous studies have revealed that women have increased prevalence of the MetS 
than men according to the IDF definition (Chien KL et al., 2008; Zabetian A et al., 2007) which 
can be related to our study.  
When using the IDF criteria, about 55.17% (n=32) of the study subjects with the MetS 
were within the age group of 60 to 79 years, subsequently 36% (n=36) and 27.27% (n=6) of the 
patients were in the age group of 40-59 and 20-39 years respectively (Table: 8 and Figure: 6). A 
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significant association was established between age and the MetS (p<0.05) through our study 
according to the IDF criteria. The prevalence of MetS was found to be highest in the age group 
of 60 to 79 years. It was observed from our study that there was a progressive development of 
the MetS in accordance with a sequential increase of the age.    
When taking into consideration the educational attainment of the study population, it was 
found that 54% (n=42), 35% (n=20) and 27% (n=12) of the patients with MetS were in ≤ 8, 9-11 
and ≥ 12 standards respectively using the IDF definitions (Table: 8 and Figure: 6). About 54% of 
the study patients with the MetS had educational qualification ≤ 8 standard. Many literatures 
have illustrated that low socio-economic status is a predictor for the MetS (Barbosa BJ et al., 
2010). Illiteracy and low income has been consistently associated with the MetS in the United 
States (Ford ES et al., 2004). In developing countries such as India, when comparing the 
previous outcome of educational status along with the MetS, it was found that majority of the 
subjects with informal (illiterates) and those with primary education had greater chances of the 
MetS because of the ignorance of health education, which is comparable to our study.  
According to the WHO classification, BMI of our patients were categorized into Normal 
weight (18.5- 24.9 kg/m
2
), Over weight (25-29.9 kg/m
2) and Obese patients (≥ 30 kg/m2). When 
using the IDF definition about 17% (n=9), 61% (n=29) and 46% (n=36) of the study patients 
with the MetS were found to be in Normal weight, over weight and obese categories respectively 
(Table: 10 and Figure: 9). In our study majority of the patients with the MetS were found to be 
‘overweight’ (61%) and ‘obese’ (46%) according to the IDF criteria. It has been stated earlier 
that obesity is linked with insulin resistance and the MetS (Carey VJ et al., 1997). Obesity 
contributes to hypertension, high serum cholesterol, low HDL-c and hyperglycemia and is 
independently related with higher CVD risk (Hu G et al., 2004; Zimmet P et al., 2001). The 
Results & Discussion 
 
A Prospective Study on Metabolic Syndrome in Patients with Cardiovascular Disease 48 
 
increase in BMI accounts for much of the increase in the prevalence of the MetS (Ford ES et al., 
2004) which can be related to our study. And also it was revealed that there was a significant 
association (p<0.05) between BMI and the MetS according to the IDF guidelines. 
Based on IDF criteria all the Laboratory and Hemodynamic variables were compared in 
our study. In the Laboratory variables, TG (OR: 1.8[95% CI: 0.88 to 3.72]; RR: 1.5[95% CI: 0.9 
to 2.7; p=0.10]) and HDL (OR: 1.08[95% CI: 0.59 to 1.97]; RR: 1.03[95% CI: 0.79 to 1.35; 
p=0.78]) revealed that the risk was not statistically significantly different. It was also revealed 
that when using the IDF criteria the results illustrated that the variables such as FBS (OR: 
3.0[95% CI: 1.6 to 5.5]; RR: 1.79[95% CI: 1.2 to 2.4; p=0.0004]), Systolic BP (OR: 7.6[95% 
CI:3.7 to 15.5]; RR: 2.26[95% CI: 1.7 to 2.9; p=0.0001]) and Diastolic BP (OR: 5.7[95% CI:2.9 
to 11.2]; RR: 2.1[95% CI: 1.5 to 2.7; p=0.0001]) had statistically significant association with the 
MetS (Table: 17). 
According to the revised NCEP ATP III definition the prevalence of the MetS was 
revealed to be 44% of the study population.  When using the NCEP ATP III criteria Hu G et al., 
(2008) revealed that the prevalence of MetS was 39.1% in Finland population and in another 
study performed by Can AS et al., (2007) using the NCEP ATP III definition established that the 
prevalence of the syndrome was 38% in Turkish adults; all these results are analogous to our 
study. The gender wise distribution showed that 32.65% (n=32) and 58.54% (n=48) of men and 
women respectively had the MetS when using the revised NCEP ATP III definition (Table: 11 
and Figure: 10). Even while using the revised NCEP ATP III definition, a higher prevalence of 
the MetS was observed in women than men. Various data substantiate to our result. For instance, 
in a study conducted by Ford ES et al., (2005) in the United States with 3601 participants with 
age ranging from 20 to 70 years, the prevalence of MetS was 34.5% according to the NCEP ATP 
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III definition (33.7% among men and 35.4% among women). Likewise, in Denmark a study was 
conducted with 2493 subjects aged between 41 and 72 years showed a 16% (14.3% for men and 
18.6% for women) according to NCEP ATP III (Jeppesen J et al., 2007). Similarly in another 
study conducted in Brazil by Barbosa BJ et al., (2010), revealed the prevalence of MetS was 
found to be 48.9% in men and 59% in women. All these studies depicted a higher prevalence of 
the MetS among women which is in accordance with our study and it was established that 
women are more prone to have MetS and the complications of CVD and T2DM. 
Based on the revised NCEP ATP III definition 72.41% (n=42) of our individuals with the 
syndrome were in the age group of 60-79 years, simultaneously 32% (n=32) and 27.27% (n=6) 
of the subjects with the MetS were within the age group of 40-59 and 20-39 years 
correspondingly (Table: 12 and Figure: 11). From our study it was established that there was 
significant association between age and prevalence of the MetS (p<0.05) according to the revised 
NCEP ATP III definition. Previous studies have illustrated that regardless of the definition of the 
MetS employed, the prevalence of MetS increases with age (Ford ES et al., 2002; Meigs JB et 
al., 2003). The prevalence of MetS in our study was found to be higher in patients with age >60 
years according to the revised NCEP ATP III definition which resembles to various studies 
(Kohli P et al., 2006; Qiao Q et al., 2009; Misra R et al., 2009). Similarly in another study 
conducted using the third National Health and Nutrition Examination Survey (NHANES III) in 
the USA, exhibited the prevalence of the MetS (defined using NCEP ATP-III criteria) was found 
to be 6.7% and 43.5% among subjects aged 20-29 years and 60-69 years of age respectively and 
was 42.0% for participants of 70 years or older (Weiss R et al., 2004). The complications 
associated with cardiovascular events increases with advancement of age. From the present study 
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it was observed that there was a gradual progress of the syndrome with the increase in age 
according to the revised NCEP ATP III definition. 
According to the revised NCEP ATP III criteria 57% (n=44), 40% (n=23) and 29% 
(n=13) of the patients with the MetS were in ≤ 8, 9-11 and ≥ 12 standards respectively (Table: 13 
and Figure: 12). From our study it was found that majority of the patients with the syndrome had 
only informal or primary education i.e. below ≤ 8 and therefore may have low socio-economic 
status and inadequate awareness of health education compared to those with education above     
≥ 12 standards.  
When considering the impact of BMI on the MetS based on the revised NCEP ATP III 
definition about 21% (n=11), 63% (n=30) and 50% (n=39) of the patients with the MetS were 
found to be Normal weight, over weight and obese correspondingly (Table: 14 and Figure: 13). 
In the study most of the patients with the MetS were ‘over-weight’ (63%) and ‘obese’ (50%) 
based on the revised NCEP ATP III criteria. Previous evidences ascertain that the chances of 
getting cardiovascular and metabolic complications are higher in ‘over weight’ and ‘obese’ 
patients (Barbosa BJ et al., 2010; Eapen D et al., 2009). Obesity can influence the development 
of other risk factors, and greater the degree of overweight, the larger the likelihood of developing 
other antecedents of atherosclerosis such as high blood pressure and type 2 Diabetes Mellitus 
(T2DM) that will increase the probability of developing CAD. Therefore it was established that 
obesity and over weight are the driving force to MetS (Ford, Giles and Mokdad, 2004). The 
present study also conforms that 63% were overweight and 50% were obese patients. The 
worldwide increase in the prevalence of obesity in the recent decades is staggering and is likely a 
cause of the rising rate of insulin resistance and the MetS. Although not all overweight or obese 
individuals are metabolically unhealthy, the majority are insulin resistant. In particular, the 
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combination of obesity, physical inactivity, and consumption of an atherogenic diet is believed to 
lead to insulin resistance. However, many studies have previously reported a positive association 
between BMI and MetS (Ford ES et al., 2004; Mangat C et al., 2010; Scott CL., 2003). Our 
study also resembles to the previous studies and it was found out that there was significant 
association (p<0.05) between BMI and the MetS according to the revised NCEP ATP III 
definition. 
When comparing the laboratory and hemodynamic variables based on the revised NCEP 
ATP III definitions, there was statistically significant association of the variables such as            
WC (RR: 2.89[95% CI: 2.15 to 3.8; p=0.0001]), FBS (RR: 2.12[95% CI: 1.5 to 2.9;  p=0.0001]), 
Systolic BP (RR: 2.71[95% CI: 1.9 to 3.6;  p=0.0001]) and Diastolic BP (RR: 2.39[95% CI: 1.76 
to 3.2;  p=0.0001]) with the MetS. The other clinical variables such as HDL-c (OR: 1.38[95% 
CI: 0.76 to 2.51]; RR: 1.15[95% CI: 0.88 to 1.49; p= 0.2802]) and TG (OR: 1.73[95% CI: 0.84 
to 3.57]; RR: 1.54[95% CI: 0.87 to 2.72; p= 0.1337]) were a contributing risk factor for the MetS 
(Tables: 18). It was known that HDL-c and TG are important clinical variables which trigger the 
MetS. Our study results revealed that there was a association between these risk factors with the 
MetS, but it was observed that these risk factors were not significantly associated with the 
syndrome. 
In our observational study two definitions were used to assess the MetS: IDF and revised 
NCEP ATP III. A total of 180 patients were assessed in this study. The prevalence of MetS was 
found to be 41% (n=74) according to the IDF definition and 44% (n=80) based on the revised 
NCEP ATP III criteria. Among the study population, the prevalence of MetS was higher 
according to both the definitions in females (51% IDF, 59% revised NCEP ATP III) than in 
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males. The age wise distribution revealed a higher prevalence of the MetS within the age group 
of 60-80 years when using both the definitions. 
Our study ascertained that nearly 1/4th of the study population was affected by the MetS, 
which is similar to the studies performed in various parts of India. In a previous study conducted 
in South India the prevalence of the MetS was estimated to be 25.8%, 23.2% and 18.3% by IDF, 
WHO and NCEP ATP III definitions respectively (Deepa M et al., 2007). The vital check points 
from our study are that prevalence of the MetS increases with advancement of age and a higher 
prevalence of the MetS was recognized in the female population. The earlier studies conducted 
in various parts of India by Ramachandran A et al., Gupta R et al., Deepa M et al., Pemminatti S 
et al., have unanimously shown similar outcomes.  
Currently economic growth, irregular timings of meals and dietary westernization has 
been recommended as possible culprits concerned in the development of the MetS. An increased 
prevalence of the MetS was observed among patients with increased BMI. The increase in the 
prevalence of metabolic derangements was related with abdominal adiposity that leads to 
morbidity and mortality (Pladevall M et al., 2006). In our study it was noted that the prevalence 
of the MetS according to both the definitions was higher in patients with BMI of  25-29.9 kg/m
2 
(Over weight) followed by ≥ 30 kg/m2 (Obese). It was recognized that the cut off values of BMI 
for the study population be set at 23 kg/m
2
. Several data have substantiated this result. Various 
studies have shown that the optimal BMI for the South Asians be maintained between 18.5 and 
23 kg/m
2 
(Eapen D et al., 2009). Another analysis of the Chennai Urban Epidemiology Study 
(CURES) also demonstrated that the optimal BMI cut-off for identifying the cardiometabolic risk 
factors was 23 kg/m
2
 for Indians of both genders (Mohan V et al., 2007). Likewise in another 
study conducted by Razak F et al., among 289 South Asian migrants residing in Canada revealed 
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that the BMI cutoff points were 22.5 kg/m
2
 for the lipid metabolism and 21 kg/m
2
 for glucose 
metabolism. Findings such as these have prompted the Indian Health Ministry to release a 
statement defining overweight in both the genders of the country as a BMI >23.0 kg/m
2
 and 
obesity as a BMI >25.0 kg/m
2
(iGovernment Press Release).  
With the MetS driving the twin global pandemic of T2DM and CVD there is a 
devastating moral, medical and economic imperative to identify those individuals with the MetS 
early, so that lifestyle interventions and treatment may prevent the development of T2DM and 
CVD.   
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6. CONCLUSION 
The Indian subcontinent is undergoing epidemiological evolution as non-communicable 
ailments like Coronary Heart Disease (CHD) and Type 2 Diabetes Mellitus (T2DM) are rapidly 
replacing infections as the primary cause of morbidity and mortality. India has developed into 
the “Diabetes Capital” of the globe and by the year 2020, is expected to have the maximum 
number of individuals suffering from cardiovascular disease (CVD) (Yusuf S, Ounpuu S., 2001). 
Approximately 7.8% of the United States (U.S) population has Diabetes Mellitus (DM), and it is 
expected that the number of patients with DM will increase to 48.3 million by 2050 in the U.S. 
and to 300 million worldwide in the year 2025, representing a 122% rise compared with 1995. 
Even though the traditional cardiovascular jeopardy factors (e.g., smoking and hypertension) are 
becoming more efficiently managed, a permanent increase of the so-called “cardiometabolic 
risk” is prominent. Early from this century, the nomenclature “Metabolic Syndrome (MetS)” has 
become more accepted to recognize a cluster of disorders together with obesity, dyslipidemia, 
hypertension, and insulin resistance. It is the most important risk factor for CVD and DM in both 
genders. Global cardiovascular jeopardy is the likelihood of affliction of a coronary episode or 
stroke deriving from risk factors including metabolic factors (total cholesterol, high-density 
lipoprotein cholesterol (HDL-c), blood glucose), hemodynamic factors (blood pressure), and 
lifestyle factors (exercise, smoking), all changeable ahead of those nonmodifiable ones such as 
age and gender. 
Ongoing investigation is required to determine how best to define the MetS. Although it 
is clear that the presence of the syndrome is associated with increased cardiovascular risk, the 
levels of associated risk have not been clearly defined. Different projected definitions would 
appear to result in diverse predictions of risk and appears to vary according to which components 
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of the proposed definitions are present. Imam et al., reported a prevalence of 79.7% from 
Pakistan, Bruno et al., reported a prevalence of 75.6% from the USA and Foucan et al., reported 
a 77% prevalence of the MetS in diabetic Indian immigrants in the USA. 
This prospective study revealed the prevalence rate of the MetS in Outpatient Department 
of Cardiology clinics among patients with CVD using the IDF criteria as 41.1% and with revised 
National Cholesterol Education Program Adult Treatment Plan III (rNCEP ATP III) criteria as 
44.4%. When studying prevalence among the genders, females were more prevalent to the 
syndrome than males which give an inference that females with MetS are prone to CVD and 
other co-morbidities. But there were no significant differences in the cardiometabolic variables, 
laboratory variables, hemodynamic variables and physical variables among male and female. 
The findings from our study showed that the prevalence of the MetS increases with age. The 
prevalence of the MetS in our subjects is high in both genders and increases with age thus posing 
a latent high cardiovascular risk. 
The imperative clinical effect of the MetS was CVD. Also the risk for T2DM is higher, 
and thereby DM is a foremost risk factor for CVD. Overall, MetS was related with a twofold 
increase in the risk of CVD and stroke, and a 1.5-fold increase in risk of all-cause mortality. 
Accordingly, individuals with MetS are at higher risk for cardiovascular outcomes than for all-
cause mortality, although these patients are at elevated risk for either outcome compared with 
those without this syndrome. 
The alarming increase in obesity especially its central component consequential in MetS, 
seems to be behind the twin pandemic of CVD and T2DM currently sweeping the Indian 
subcontinent. From our study it was revealed that sedentary life-style and increased popularity 
and easy-availability of energy-dense food are the dynamic force for this increasing hazard. It 
Conclusion 
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was found that in people without the syndrome has atleast one component of MetS and may 
therefore be at an increased risk of cardiometabolic syndrome.  And therefore community based 
programmes to promote healthy living are needed to embark upon this catastrophe. Physicians 
along with pharmacist and other healthcare professionals have a very important role to play in 
this endeavor. Therefore larger prospective studies in other parts of India are necessary to 
recognize the prevalence of the MetS along with the risk factors associated in cross sectional 
population and in specific groups of high-risk patients. 
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